Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478948 | 1.00 | RXRA (0.38) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL29384146 | 0.88 | CYP4F2 (0.39) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL16647245 | 0.88 | CYP4F2 (0.39) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL23546535 | 0.87 | RXRA (0.36) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL25795327 | 0.87 | RXRA (0.40) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL30641330 | 0.86 | RXRA (0.38) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL29418904 | 0.86 | CYP4F2 (0.36) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL21243898 | 0.86 | CYP4F2 (0.36) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL26674786 | 0.86 | RXRA (0.38) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL24373802 | 0.85 | RXRA (0.37) | RXRARXRBRXRGDGAT2CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117425649-A | Pyrazole derivatives as KRAS mutein inhibitors | 诺华股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| WO-2023220831-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-11-23 | — | — | WO | disclosed |
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | NOVARTIS AG (CH) | 2023-07-18 | — | — | US | disclosed |
| WO-2022269508-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022083569-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2021124222-A1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021120890-A1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| US-10774082-B2 | Quinazoline compound | ASTELLAS PHARMA INC. (JP) | 2020-09-15 | — | — | US | disclosed |
| US-20200140437-A1 | QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2020-05-07 | — | — | US | disclosed |
| US-10556906-B2 | Quinazoline compound | ASTELLAS PHARMA INC. (JP) | 2020-02-11 | — | — | US | disclosed |
| US-20190292182-A1 | QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140437-A1 | QUINAZOLINE COMPOUND | KRAS, NRAS, HRAS | RXRA 4341/4885RXRB 4489/4885RXRG 3879/4885 |
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | PAK5, CYP51A1, SF3B5 | RXRA 3302/4885RXRB 3437/4885RXRG 3379/4885 |
| US-10556906-B2 | Quinazoline compound | KRAS, NRAS, HRAS | RXRA 4341/4885RXRB 4489/4885RXRG 3879/4885 |
| US-20190292182-A1 | QUINAZOLINE COMPOUND | KRAS, NRAS, HRAS | RXRA 4341/4885RXRB 4489/4885RXRG 3879/4885 |
| US-10774082-B2 | Quinazoline compound | KRAS, NRAS, HRAS | RXRA 4341/4885RXRB 4489/4885RXRG 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.